search

Active clinical trials for "Hepatic Encephalopathy"

Results 91-100 of 180

Rifaximin in Minimal Hepatic Encephalopathy

Hepatic Encephalopathy

The purpose of this study is to determine whether alteration of gut flora with rifaximin can lead to improvement in driving performance, psychometric test performance, and quality of life in patients with minimal hepatic encephalopathy (MHE) and cirrhosis in a randomized, blinded, placebo-controlled trial.

Completed20 enrollment criteria

Feasibility of an App-based Nutrition & Exercise Program in Cirrhosis

CirrhosisLiver1 more

The personalized nutrition and exercise app was designed for use by individuals living with chronic conditions. The pilot study examines the acceptance and use of the online, interactive program to support self-management in cirrhosis.

Completed13 enrollment criteria

The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy.

CirrhosisAscites4 more

This study is being completed for patients with cirrhosis, including patients with a prior history of hepatic encephalopathy (HE) to evaluate the feasibility and benefits of medically-tailored meals as an intervention. Patients will be enrolled from the University of Michigan and will complete the baseline assessments in-person or remotely. In addition participants will complete study related materials before, during and after treatment with medically-tailored meals (MTM). After completing the study meals, participants will return for follow-up or have this visit completed remotely as well as have an observational period for 12 more weeks.

Completed19 enrollment criteria

Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double...

Hepatic Encephalopathy

The study will be double blind with respect to rifaximin, and randomization will be performed using tables of computer-generated random numbers. All subjects will be followed up till the recovery of HE (primary end point) or 10 days whichever is earlier. In the Lactulose group (group A) patients will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passes 2-3 semisoft stools per day along with placebo . In the lactulose plus rifaximin group (group B) patients will receive cap rifaximin 400mg three times a day along with lactulose. Primary endpoints will be recovery of overt HE patients who will not recover from HE after 10 days will be continued on the same treatment. Total duration of the study is 1 year.

Completed10 enrollment criteria

Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy...

Hepatic CirrhosisMinimal Hepatic Encephalopathy

Hepatic encephalopathy is a serious complication of cirrhosis which relays under the burden of diseases with therapeutical difficulties for its given morbidity and mortality and the high recurrence it poses. Its treatment remains a challenge for most of the cases. Even more, minimal hepatic encephalopathy is an entity that has an additional morbidity for it being a subclinical entity. As so, the investigators propose an auxiliary treatment for the management of such patients with minimal hepatic encephalopathy, using a specific diet consisting on hyperproteic and fibre-rich foods along with two independent interventions, whether a probiotic, lactobacillus reuteri, or a drug, nitozoxanide, so to diminish the rate of progression to any clinical stage of hepatic encephalopathy and to revert minimal hepatic encephalopathy itself to none hepatic encephalopathy.

Completed14 enrollment criteria

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent...

Hepatic EncephalopathyCirrhosis

The purpose of the study is to evaluate if rifaximin alone or rifaximin plus lactulose delays the onset of hepatic encephalopathy (HE) in participants with cirrhosis who have had a previous episode of HE.

Completed15 enrollment criteria

Effect of Tolvaptan on Cognitive Function in Cirrhosis

CirrhosisHepatic Encephalopathy1 more

Hypothesis: Tolvaptan will improve cognitive function, brain edema and health-related quality of life in cirrhotic patients with hyponatremia

Completed18 enrollment criteria

Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration

Hepatic Encephalopathy

This study is being done to assess the safety and efficacy of using mobile application-based Bristol stool scale to titrate lactulose in prevention episodes of hepatic encephalopathy.

Completed6 enrollment criteria

Oral Fecal Transplant in Cirrhosis

Hepatic EncephalopathyCirrhosis1 more

To evaluate the safety and tolerability of oral fecal transplant in patients with cirrhosis and hepatic encephalopathy

Completed5 enrollment criteria

Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.)

Hepatic EncephalopathyHE3 more

The purpose of this study is to evaluate whether the use of polyethylene glycol is superior and more safe in treating hepatic encephalopathy compared to lactulose and also to determine if treatment with polyethylene glycol will reduce the duration of hospital stay.

Withdrawn14 enrollment criteria
1...91011...18

Need Help? Contact our team!


We'll reach out to this number within 24 hrs